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planned hospitalization. Full course of radiotherapy can be 
safely used in older patients but they have a low tolerance to 
chemotherapy and frequently require dose-reduction; the 
effect of this chemotherapy is uncertain.  
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Purpose/Objective: Various guidelines, including UK NICE 
guidance recommend a minimum of 74 Gy for prostate cancer 
radiotherapy. So we escalated prostate radiation dose to 74 
Gy (2Gy per #) in our department. We previously found that 
elderly patients were able to tolerate radiotherapy (RT) very 
well when median RT dose was 70 Gy (Data published 2006). 
Following RT dose escalation, we analysed our prospectively 
collected, rectal toxicity data in our department. 
Materials and Methods: All patients (pts) treated with 
prostate radiotherapy between August 2010 and July 2011, 
were identified from MOSAIC Software (Elekta). Pts who had 
prostate-bed radiotherapy, whole pelvis RT or HDR boost 
were excluded. The regional ethics committee advised that 
formal ethics approval was not necessary. 
Results: 132 patients were identified; median age was 70.5 
years, ( range 53 to 81 yrs). Median PSA was 13 (range 4.2 to 
133). Gleason scores: G6 4.5%, G7 51.5%, G8 21.2%, G9 18.2% 
G10 2.3% (missing data 2.3%). Tumour stage: T1 8.3%, T2 
55.3%, T3 32.6%, T4 0% (missing data 3.8%). Median total 
radiation dose was 74Gy (range 66Gy to 78Gy). (66 Gy is an 
outlier due to dosimetric problems caused by bilateral hip 
replacement). Age was significantly associated with rectal 
toxicity. Patients aged over 75 were almost 3.5 times more 
likely to develop ≥ grade 2 toxicity (p=0.026). Absolute total 
rectal volume outlined ( in cc) was also significantly 
associated with rectal toxicity. Pts having maximum rectal 
volume of more than 46cc were 3.8 times more likely to 
develop ≥ grade 2 toxicity (p=0.03 chi squared test). The 
rectal DVH parameters for 30Gy, 50Gy, and 60Gy were 
significantly associated with rectal toxicity .(p=0.038; 
p=0.016 and p=0.002 respectively). The absolute-volume 
parameters were consistently and better correlated with 
rectal toxicity than percentage-volume parameters. Median 
absolute rectal volume for patients with ≥grade 2 acute 
rectal toxicity was significantly higher than for those with 
grade 0/1 toxicity (p=0.018). By contrast, the difference 
between median percentage-Volume was not significant 
(p=0.345). The following Absolute-volume DVH constraints 
were most significantly correlated with rectal toxicity. 
V30≤42cc, V50≤40cc, V60≤35cc. 
Conclusions: Our real world data, from an unselected 
population of pts indicate elderly pts ( > 75 years) are at 
increased risk of rectal toxicity. If rectal DVH parameters are 
not optimal, elderly prostate pts should be considered for 
radiation dose reduction as patient preference studies 
indicate that lot of patients prefer lower toxicity over 
efficacy. (van Tol-Geerdink et al. J Clin Oncol. 2006: 24: 
4581). 
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Purpose/Objective: The incidence of cancer in the elderly is 
expected to rise . For example in the USA it is estimated that 
it will rise by 67% between 2010 to 2030. This is a 
retrospective analysis audit on radiotherapy to the very 
elderly defined as patients above 80 years old from Jan 2012 
until Dec 2013. We hope to analyse the radiotherapy intent; 
tumour site analysis and median survival days from the last 
fraction of radiotherapy. With these understanding, we hope 
to be able to further better or understanding and plan 
management for our very elderly who are under our care in 
future. 
Materials and Methods: We retrospectively collected and 
analysed the data from our Aria database for all patients 
above 80 years old on the day they finished treatment from 
January 2012 until Dec 2013. 
Results: We treated 1571 patients who were very elderly 
during these analysed 2 years. 40% of our very elderly were 
treated with radical intent. Nearly 25% of them were patients 
treated for Breast Cancer followed by Lung Cancer (20%). 
There was nearly an equal distribution with 51% of them 
being male patients. The median days from time of last 
fraction of radiotherapy to death was 129 days with a 
maximum of 826 days at time of analysis. Palliative 
treatments to the very elderly were mainly palliation for 
bone metastases and lung/ chest palliation. 
Conclusions: There is a high proportion of the very elderly 
treated with radical intent with radiotherapy; with Breast 
and Lung Cancer being the highest malignant cause. There 
was a fairly equal sex distribution between those treated for 
radiotherapy in the very elderly. We need to further analyse 
these data to provide a more meaning insight in order to 
improve and adequately support our very elderly requiring 
treatment. 
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Purpose/Objective: the incidence of esophageal cancer is 
increasing. Additionally, an increasing number of patients are 
older than 75 years. Since the publication of the CROSS trial 
in 2012, preoperative chemoradiation (CRT) followed by 
